March 02, 2023 — 07:51 am EST

      Written by
                        RTTNews.com for                             
        




RTTNews ->


(RTTNews) - Checkpoint Therapeutics, Inc. (CKPT) announced the FDA has accepted for filing the Biologics License Application for cosibelimab, an investigational anti-PD-L1 antibody, as a treatment for patients with metastatic cutaneous squamous cell carcinoma or locally advanced cSCC who are not candidates for curative surgery or radiation. The FDA has set a PDUFA goal date of January 3, 2024. 
The FDA indicated that no potential filing review issues have been identified, and that an advisory committee meeting to discuss the application is not currently planned.
The company said its BLA submission is supported by the positive results from registration-enabling clinical trial evaluating cosibelimab in patients with metastatic and locally advanced cSCC.
For More Such Health News, visit rttnews.com. 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

© 2023, Nasdaq, Inc. All Rights Reserved.










To add symbols:


These symbols will be available throughout the site during your session.
To add symbols:


These symbols will be available throughout the site during your session.